STOCK MARKET BSE NSE

Roche, Glenmark Settle Tarceva Patent Row

Published: 02nd January 2016 03:17 AM  |   Last Updated: 02nd January 2016 03:17 AM   |  A+A-

CHENNAI: In a significant move, Swiss pharma firm Roche and India's Glenmark Pharmaceuticals have settled an out-of-court patent litigation over the former's lung cancer drug erlotinib hydrochloride sold under the brand name 'Tarceva.' 

"Glenmark and Roche/OSI confirm that they have reached an agreement regarding ongoing patent disputes relating to the anti-cancer medicine Erlotinib Hydrochloride," the two companies said in a joint statement on Friday.

Roche, which was granted patent in India for erlotinib hydrochloride on Feb 23, 2007, was embroiled in patent disputes with another desi  pharma firm, Cipla over Tarceva.

In November last year, Roche had successfully defended its patent in the Delhi High Court against Cipla. The court had ruled that Cipla's generic version of the drug infringed Roche's Tarceva patent.

"As part of the agreement, the companies have ceased all relevant patent litigation on this product and Glenmark has acknowledged the patent rights of Roche," it added.

Tarceva is developed and commercialised by Astellas Pharma US in partnership with Genentech in the United States, Chugai in Japan and Roche in the rest of the world. It is a once-daily, oral non-chemotherapy medicine.

More from Business.

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp